Therapy with a Janus kinase (JAK) inhibitor may be associated with development of acne.

Clinical features:

(1) development of acne in a patient treated with a JAK inhibitor

(2) absence of acne prior to starting therapy

(3) improvement in the skin lesions upon discontinuation or reduction in dosage

(4) no alternative explanation for the acne


The severity of the acne is typically mild or moderate and is rarely an indication for drug discontinuation.

To read more or access our algorithms and calculators, please log in or register.